MOREPENLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Morepen Laboratories has submitted its Annual Secretarial Compliance Report for the financial year ended 31 March 2025, signed by Practicing Company Secretary Praveen Dua. The company is broadly compliant with SEBI regulations, listing rules, secretarial standards, related-party transaction norms, insider trading rules, and disclosure obligations, with no penalties or actions imposed by SEBI or the stock exchanges. The only flagged item is that the Register of Members has not been updated to reflect the cancellation of 50,62,872 equity shares (out of 92,490,413 issued to FD holders) done pursuant to an NCLT Chandigarh order. Both BSE and NSE have declined to act on the company's request to reflect this cancellation in the listed capital, and the company is still exploring the way forward. This same observation was carried over from the FY24 report, indicating an unresolved legacy compliance issue.
This is a routine regulatory filing with no financial penalty or operational impact, so the stock price is unlikely to react. However, investors should note the pending share cancellation matter as an unresolved compliance item that could affect the company's reported share capital once settled.